WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 596545
CAS#: 7035-04-3
Description: Pyridarone is a bioactive chemical.
MedKoo Cat#: 596545
Name: Pyridarone
CAS#: 7035-04-3
Chemical Formula: C13H9NO
Exact Mass: 195.0684
Molecular Weight: 195.22
Elemental Analysis: C, 79.98; H, 4.65; N, 7.17; O, 8.20
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Pyridarone; L-4269; L 4269;L4269; Pyridaronum; Piridarona;
IUPAC/Chemical Name: 4-(benzofuran-2-yl)pyridine
InChi Key: LGTULKCVKOMQDR-UHFFFAOYSA-N
InChi Code: InChI=1S/C13H9NO/c1-2-4-12-11(3-1)9-13(15-12)10-5-7-14-8-6-10/h1-9H
SMILES Code: C1(C2=CC3=CC=CC=C3O2)=CC=NC=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 195.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Kilic B, Gulcan HO, Aksakal F, Ercetin T, Oruklu N, Umit Bagriacik E, Dogruer DS. Design and synthesis of some new carboxamide and propanamide derivatives bearing phenylpyridazine as a core ring and the investigation of their inhibitory potential on in-vitro acetylcholinesterase and butyrylcholinesterase. Bioorg Chem. 2018 May 8;79:235-249. doi: 10.1016/j.bioorg.2018.05.006. [Epub ahead of print] PubMed PMID: 29775949.
2: Versteegen RM, Ten W, Rossin R, de Geus MA, Janssen HM, Robillard MS. Click-to-Release from trans-cyclooctenes: mechanistic insights and expansion of scope from established carbamate to remarkable ether cleavage. Angew Chem Int Ed Engl. 2018 May 10. doi: 10.1002/anie.201800402. [Epub ahead of print] PubMed PMID: 29746709.
3: Duke AN, Meng Z, Platt DM, Atack JR, Dawson GR, Reynolds DS, Tiruveedhula VVNPB, Li G, Stephen MR, Sieghart W, Cook JM, Rowlett JK. Evidence that Sedative Effects of Benzodiazepines Involve Unexpected GABA(A) Receptor Subtypes: Quantitative Observation Studies in Rhesus Monkeys. J Pharmacol Exp Ther. 2018 May 2. pii: jpet.118.249250. doi: 10.1124/jpet.118.249250. [Epub ahead of print] PubMed PMID: 29720564.
4: Garcia DG, Gonçalves-de-Albuquerque CF, da Silva CI, Kiss R, Dasari R, Chandra S, Kornienko A, Burth P. Effect of polygodial and its direct derivatives on the mammalian Na(+)/K(+)-ATPase activity. Eur J Pharmacol. 2018 Jul 15;831:1-8. doi: 10.1016/j.ejphar.2018.04.031. Epub 2018 Apr 30. PubMed PMID: 29715454.
5: Dey R, Kumar P, Banerjee P. Lewis Acid Catalyzed Annulation of Cyclopropane Carbaldehydes and Aryl Hydrazines: Construction of Tetrahydropyridazines and Application Toward a One-Pot Synthesis of Hexahydropyrrolo[1,2- b]pyridazines. J Org Chem. 2018 May 18;83(10):5438-5449. doi: 10.1021/acs.joc.8b00332. Epub 2018 May 2. PubMed PMID: 29693383.
6: Park YD, Kim JJ, Lee S, Park CH, Bai HW, Lee SS. A Pyridazine-Based Fluorescent Probe Targeting Aβ Plaques in Alzheimer's Disease. J Anal Methods Chem. 2018 Feb 27;2018:1651989. doi: 10.1155/2018/1651989. eCollection 2018. PubMed PMID: 29682395; PubMed Central PMCID: PMC5848141.
7: Patil RB, Barbosa EG, Sangshetti JN, Sawant SD, Zambre VP. LQTA-R: A new 3D-QSAR methodology applied to a set of DGAT1 inhibitors. Comput Biol Chem. 2018 Mar 1;74:123-131. doi: 10.1016/j.compbiolchem.2018.02.021. [Epub ahead of print] PubMed PMID: 29602042.
8: Moine E, Moiré N, Dimier-Poisson I, Brunet K, Couet W, Colas C, Van Langendonck N, Enguehard-Gueiffier C, Gueiffier A, Héraut B, Denevault-Sabourin C, Debierre-Grockiego F. Imidazo[1,2-b]pyridazines targeting Toxoplasma gondii calcium-dependent protein kinase 1 decrease the parasite burden in mice with acute toxoplasmosis. Int J Parasitol. 2018 Jun;48(7):561-568. doi: 10.1016/j.ijpara.2017.12.006. Epub 2018 Mar 7. PubMed PMID: 29524527.
9: Tokumaru K, Bera K, Johnston JN. 1,3,4-Oxadiazole and Heteroaromatic-Fused 1,2,4-Triazole Synthesis using Diverted Umpolung Amide Synthesis. Synthesis (Stuttg). 2017 Oct;49(20):4670-4675. doi: 10.1055/s-0036-1590802. Epub 2017 Aug 7. PubMed PMID: 29507449; PubMed Central PMCID: PMC5833303.
10: Hu Z, Wang C, Han W, Rossi KA, Bozarth JM, Wu Y, Sheriff S, Myers JE Jr., Luettgen JM, Seiffert DA, Wexler RR, Quan ML. Pyridazine and pyridazinone derivatives as potent and selective factor XIa inhibitors. Bioorg Med Chem Lett. 2018 Apr 1;28(6):987-992. doi: 10.1016/j.bmcl.2018.02.049. Epub 2018 Feb 27. PubMed PMID: 29501396.
11: Shen B, Geiger T, Einholz R, Reicherter F, Schundelmeier S, Maichle-Mössmer C, Speiser B, Bettinger HF. Bridging the Gap between Pentacene and Perfluoropentacene: Synthesis and Characterization of 2,3,9,10-Tetrafluoropentacene in the Neutral, Cationic, and Dicationic States. J Org Chem. 2018 Mar 16;83(6):3149-3158. doi: 10.1021/acs.joc.7b03241. Epub 2018 Feb 27. PubMed PMID: 29485868.
12: Schulz U, Grossmann A, Wilde F, Freitag M, Lemmerhirt C, Schulzke C, Link A, Morgenstern O. Synthesis, chemical behavior, structure elucidation and iNOS inhibitory activity of 1-substituted 3-methylsulfanyl-5,6,7,8-tetrahydro-1H-[1,2,4]triazolo[1,2-a]pyridazines(). Pharmazie. 2017 Jul 3;72(7):371-382. doi: 10.1691/ph.2017.6902. PubMed PMID: 29441933.
13: Kaczmarek AM, Esquivel D, Laforce B, Vincze L, Van Der Voort P, Romero-Salguero FJ, Van Deun R. Luminescent thermometer based on Eu(3+) /Tb(3+) -organic-functionalized mesoporous silica. Luminescence. 2018 May;33(3):567-573. doi: 10.1002/bio.3447. Epub 2018 Jan 25. PubMed PMID: 29369466.
14: Saraswat M, Venkataramani S. Through bond and through space interactions in dehydro-diazine radicals: a case study of 3c-5e interactions. Phys Chem Chem Phys. 2018 Feb 7;20(6):4386-4395. doi: 10.1039/c7cp07579k. PubMed PMID: 29369313.
15: Abu-Hashem AA, El-Shazly M. Synthesis of New Isoxazole-, Pyridazine-, Pyrimidopyrazines and Their Anti-Inflammatory and Analgesic Activity. Med Chem. 2018;14(4):356-371. doi: 10.2174/1573406414666180112110947. PubMed PMID: 29332598.
16: Prek B, Stanovnik B. The Synthesis of 7-Substituted-2,3-dihydropyrido [4,3-d]pyridazine-1,4-diones and 1,4-Dioxo-7-substituted-1,2,3,4-tetrahydropyrido[4,3-d]pyridazine 6-Oxides from Methyl Ketones. Acta Chim Slov. 2017 Dec;64(4):798-803. PubMed PMID: 29318308.
17: Jacobs M, Greff Da Silveira L, Prampolini G, Livotto PR, Cacelli I. Interaction Energy Landscapes of Aromatic Heterocycles through a Reliable yet Affordable Computational Approach. J Chem Theory Comput. 2018 Feb 13;14(2):543-556. doi: 10.1021/acs.jctc.7b00602. Epub 2018 Jan 24. PubMed PMID: 29300481.
18: Kaieda A, Takahashi M, Takai T, Goto M, Miyazaki T, Hori Y, Unno S, Kawamoto T, Tanaka T, Itono S, Takagi T, Hamada T, Shirasaki M, Okada K, Snell G, Bragstad K, Sang BC, Uchikawa O, Miwatashi S. Structure-based design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine-based p38 MAP kinase inhibitors. Bioorg Med Chem. 2018 Feb 1;26(3):647-660. doi: 10.1016/j.bmc.2017.12.031. Epub 2017 Dec 24. PubMed PMID: 29291937.
19: Mohamed MS, Abdelhamid AO, Almutairi FM, Ali AG, Bishr MK. Induction of apoptosis by pyrazolo[3,4-d]pyridazine derivative in lung cancer cells via disruption of Bcl-2/Bax expression balance. Bioorg Med Chem. 2018 Feb 1;26(3):623-629. doi: 10.1016/j.bmc.2017.12.026. Epub 2017 Dec 20. PubMed PMID: 29290491.
20: Jiang Y, Yau MK, Lim J, Wu KC, Xu W, Suen JY, Fairlie DP. A Potent Antagonist of Protease-Activated Receptor 2 That Inhibits Multiple Signaling Functions in Human Cancer Cells. J Pharmacol Exp Ther. 2018 Feb;364(2):246-257. doi: 10.1124/jpet.117.245027. Epub 2017 Dec 20. PubMed PMID: 29263243.